Find and Join

• Let’s talk about that Lilly announcement

  There’s been plenty of coverage of Eli Lilly’s announcement this week that it will sell vials of Zepbound directly to consumers at a discount. But the company seems to have left out a few important caveats. read more →

• Our response to the op-ed in The Hill

  The Hill published an editorial by Dr. Kenneth McCall titled “Fake, unsafe weight-loss drugs are a worsening public health dilemma” in which he makes unfounded claims about pharmacy compounding. Here’s the response from our CEO. read more →

• The shortage ends … then what? (Find out at CCH) 

  We’ve added a new session to the Compounders on Capitol Hill lineup. Don’t miss the discussion of what’s on many a compounder’s (and regulators’ … and reporters’...) mind. read more →

• A new bronze corporate patron

  A big welcome to Ro, APC’s newest tier-level corporate patron! read more →

• Education (and CE) from USP

  For the fourth year in a row, USP will be holding a hybrid live/virtual workshop dedicated to improving the quality of compounding. read more →

• Compounding post-Chevron

  At least three issues affecting pharmacy compounding might be affected by the overturning of the decades-old “Chevron doctrine.” read more →

• 503B sourcing: our state-by-state analysis

  Do you work for one of APC’s PFMs? If you’re with a Pharmacy/Facility Member, you’ve got access to a new resource. read more →

• What we’ll be talking about at CCH

  When we get together on Capitol Hill to meet with legislators and their staffs, as much as we’d like to talk about a half-dozen issues (easily!), we’re going to be focusing on the three most important.  read more →

More News

Responding to a question from Congresswoman Diana Harshbarger (TN) during a recent Energy & Commerce Health Subcommittee Hearing on “Preparing for and Responding to Future Public Health Security Threats,” FDA Commissioner Dr. Robert Califf acknowledged the importance of compounding for addressing drug shortages during emergencies.

He also indicated that a permanent solution or guidance on the flexibility of compounding pharmacies could be a good thing to work on.

Additionally, Rep. Harshbarger questioned whether the FDA’s shortage list accurately captures regional and wholesale level shortages. Dr. Califf agreed that the current system is subjective and could be improved, particularly in understanding the total distribution system. The possibility of recognizing the American Society of Health System pharmacist shortage listing was also raised, with Dr. Califf stating that everything is on the table for consideration.

We are very grateful to Rep. Harshbarger (who is also an APC member) for raising these issues for discussion.